Apolipoprotein E: A major piece in the Alzheimer's disease puzzle

Journal of Cellular and Molecular Medicine

Volumn 5, Issue 3, 2001, Pages 254-266

  Cedazo Minguez A ^a   Cowburn, R F ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; Apolipoprotein E; Cell signalling oxidative stress; Synaptic plasticity

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL;

ALZHEIMER DISEASE; HUMAN; LIPID METABOLISM; METABOLISM; REVIEW;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHOLESTEROL; HUMANS; LIPID METABOLISM;

EID: 0035527316     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2001.tb00159.x     Document Type: Article

References (67)

1. Selkoe D.J., Alzheimer's Disease: Genes, Proteins and Therapy, Phys. Rev., 81:741-766, 2001
2. Kehoe P., Wavrant-De Vrieze .F, Crook R., Wu W.S., Holmans P., Fenton L, Spurlock G., Norton N., Williams H., Williams N., Lovestone S., PerezTur J., Hutton M., Chartier-Harlin M.C., Shears S., Roehl K., Booth J., Van Voorst W, Ramie D., Williams J., Goate A., Hardy J., Owen M J., A full genome scan for late onset Alzheimer's disease, Hum. Mol. Genet., 8:237-45, 1999
3. Beffert U., Danik M., Krzykowski P., Ramassamy C., Berrada F., Poirier J., The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease, Brain Res. Rev., 27:119-142, 1998
4. Weisgraber K.H. and Mahley R.W., Human apolipoprotein E: the Alzheimer's Disease connection, FASEB J., 10:1485-1494, 1996
5. Baskin F., Smith G.M., Fosmire J.A., Rosenberg R.N, Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures, J. Neural. Sei, 148:15-8, 1997
6. Stone D.J., Rozovsky I., Morgan T.E., Anderson C.P., Hajian H., Finch C.E., Astrocytes and microglia respond to estrogen with increased apoE mRNA HI vivo and HI vi'rro, Exp. Neural., 143: 3138, 1997
7. Cedazo-Minguez A., Hamker U., Veh H., Meske V., Albert F., Cowburn R.F., Ohm T.G, Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures, Neuroscience, 105:651-661,2001
8. Forstner M., Peters-Libeu C., Contreras-Forrest E., Newhouse Y., Knapp M., Rupp B., Weisgraber K. H., Carboxyl-terminal domain of human apolipoprotein E: expression, purification, and crystallization, Protein Expr. Purif., 17:267-272, 1999
9. Smith J.D., Apolipoprotein E4: an allele associated with many diseases, Ann. Med., 32:118-127, 2000
10. Pericak-Vance M.A., Bebout J.L., Gaskell P.CJr., Yamaoka L.H., Hung W.Y., Alberts M.J., Walker A.P., Bartlett RJ., Haynes C.A., Welsh K.A., Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage, Am. J. Hum. Genet., 48:1034-50, 1991
11. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small GW., Roses A.D., Haines J.L., Pericak-Vance M.A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261:921-923, 1993
12. Rubinsztein D.C, Easton D.F., Apolipoprotein E genetic variation and Alzheimer's disease. A metaanalysis, Dement. Geriatr. Cogn. Disord., 10:199209, 1999
13. Bullido M.J., Artiga M.J., Recuero M., Sastre I., Garcia M.A., Aldudo J., Lendon C., Han S.W., Morris J.C., Frank A., Va/quez J., Goate A., Valdivieso F., A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia, Nat. Genet., 18:69-71, 1998
14. Lambert J.C., Pasquier F., Cottel D., Frigard B., Amouyel P., Chartier-Harlin M.C. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease, Hum. Mol. Genet., 7:533-40, 1998
15. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K., Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, Brain Res., 541:163-6, 1991
16. Wisniewski T., Frangione B., Apolipoprotein E: a patohological chaperone protein with cerebral and systemic amyloid, Nenrosci Lett., 135:235-238, 1992
17. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D., Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease, Proc. Natl. Acad. Sci. USA, 90:1977-1981, 1993.
18. Permanne B., Perez C., Soto C., Frangione B., and Wisniewski T., Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants, Biochem. Biophys. Res. Commun., 270:715-720, 1997
19. Wisniewski T., Castano E., Golabek A., Vogel T., Fragione B., Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro, Am. J. Patlwl, 145:1030-1035, 1994
20. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M., Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease, Proc. Nat. Acad. Sci. USA, 96:5233-8, 1999
21. LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, GS., Frail, D.E., Isoformspecific binding of apolipoprotein E to betaamyloid, J. Biol. Chem., 269:23403-23406, 1994
22. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M., Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease, J. Clin. Invest., 103:R15R21, 1999
23. Kuo Y.M., Crawford F., Mullan M., Kokjohn T.A., Emmerling M.R., Weller R.O., Roher A.E., Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease, Mol. Med., 6:430-9, 2000
24. Buée L., Bussiere T., Buée-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 33:95-130, 2000
25. Strittmatter W.J., WeisgraberK.H., Goedert M., Saunders A.M., Huang D., Corder E.H., Dong L.M., Jakes R., Alberts M.J., Gilbert J.R., Han S.H., Hulette C., Einstein G, Schmechel D., Pericak-Vance M.A., Roses A.D., Hypothesis: microtubule instability and paired helical filament formation in the Alzheimers disease brain are related to apolipoprotein E genotype, Exp. Neurol., 125: 163-171, 1994
26. DeMattos R.B., Curtiss L.K., Williams D.L., A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins, J. Biol. Chem., 273:4206-4212, 1998
27. Genis I., Fisher A., Michaelson D.M., Site-specific dephosphorylation of tau of apolipoprotein Edeficient and control mice by Ml muscarinic agonist treatment, J. Neurochein., 72:206-13, .1999
28. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F., Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tan in the brains of transgenic mice, Am. J. Pathol., 156:951-64, 2000
29. Lovestone S., Anderton B.H., Hartley C., Jensen T.G, Jorgensen A.L., The intracellular Fate of apolipoprotein E is tan dependent and apoE allele specific, NenroReport, 7:1005-1008, 1996
30. DeMattos R.B., Thorngate F.E., Williams D.L., A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic,J. Neurosci., 19:2464-73, 1999
31. Muller W., Meske V., Berlin K., Scharnagl H., März W., Ohm T.G, Apolipoprotein E isoforms increase intracellular Ca2+ differentially through a omega-agatoxin IVa-sensitive Ca2+-channel, Brain Pathol., 8:641-653, 1998
32. Wang X., Luebbe P., Gruenstein E., Zemlan, F., Apolipoprotein E (ApoE) peptide regulates tau phosphorylation via two different signaling pathways, 7. Neurosci. Res., 51:658-665, 1998
33. Kampers T., Pangalos M., Geerts H., Wiech H., Mandelkow, E., Assembly of paired helical filaments from mouse tan: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease, FEBS Lett., 451:3944,1999
34. Cedazo-Minguez A., Wiehager B., Huettinger M., Winblad B., Cowburn R.F., Effects of apolipoprotein E (apoE) isoforms, β-amyloid (Aβ) (1-42), and apoE/Aβ complexes on Protein Kinase C-cc (PKC-a) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts, Nenrochem. Int., 38:615-625,2001
35. Pei J-J., Braak E., Braak H., Grundke-Iqbal I., Iqbal, K., Winblad B., Cowburn R.F., Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes,/ Neuropath. Exp. Neural, 58:1010-1019, 1999
36. Gibb G, Pearce J., Betts J.C., Lovestone S., Hoffmann M.M., Maerz W, Blackstock W.P., Anderton, B.H. Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase3βidentified by nano-electrospray mass spectrometry, FEBS Lett., 485:99-103, 2001
37. Takashima A., Murayama M., Murayama O., Kohno T., Honda T., Yasutake K., Nihonmatsu N., Mercken M., Yamaguchi H., Sugihara S., Wolozin B., Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau, Proc. Natl. Acad. Sci. USA, 95:9637-41, 1998
38. Behrens J., von Kries J.P., Kühl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W., Functional interaction of beta-catenin with the transcription factor LEF-1, Nature, 382:638-42, 1996
39. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., devers H., Saftig P., De Strooper B., He X., Yankner B.A., Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis, Nature, 395:698702, 1998
40. Ohkubo N., Mitsuda N., Tamatini M., Yamaguchi A., Lee Y-D., Ogihara T., Vitek M.P., Tohyama, M., Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular kinase signal-regulated kinase pathway, J. Biol. Chem., 276:3046-3053, 2001
41. Crutcher K.A., Clay M.A., Scott S.A., Tian X., Tolar M., Harmony J.A., Neurite degeneration elicited by apolipoprotein E peptides, Exp. Neural., 130:120-126, 1994
42. Tolar M., Marques M., Harmony J., Crutcher K., Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E related synthetic peptides is receptor mediated, J. NeuroscL, 17:56785686, 1997
43. Montine K.S., Reich E., Neely M.D., Sidell K.R., Oison S.J., Markesbery W.R., Montine, T.J., Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype, J. Neuropathol. Exp. Neural., 57:415-25, 1997
44. Ramassamy C., Averill D., Beffert U., Theroux L., Lussier-Cacan S., Cohn J. S., Christen Y., Schoofs A., Davignon J., Poirier, J., Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain, Neurobiol. Dis., 7:23-37. 2000
45. Ma J., Brewer H.B. Jr., Potter H., Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides, Neurobiol. Aging, 17:773-80, 1996
46. Whitson J.S., Mims M.P., Strittmatter W.J., Yamaki T., Morrisett J.D., Appel S.H., Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E, Biochem. Biophys. Res. Commun., 199:163-70, 1994
47. Miyata M. and Smith J.D. Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides, Nat. Genet., 14:55-61, 1996
48. Pedersen W.A., Chan S.L., Mattson M.P., A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal, J. Neurochem., 74: 1426-33, 2000
49. Buttini M, Akeefe H, Lin C, Mahley R.W., Pitas R.E., Wyss-Coray T., Mucke L., Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease, Neitroscience, 97:207-10, 2000
50. Hashimoto Y., Jiang H., Niikura T., Ito Y., Hagiwara A., Umezawa K., Abe Y., Mutuyama Y., Nishimoto I., Neuronal apoptosis by apolipoprotein E4 through low-density lipopprotein receptorrelated protein and heterotrimeric GTPases, J. NeuroscL, 15:8401-8409, 2000
51. Moulder K.L., Narita M., Chang L.K., Bu G, Johnson E.M. Jr., Analysis of a novel mechanism of neuronal toxicity produced by an apolipoprotein Ederived peptide, J. Nenrochein., 72:1069-80, 1999
52. Cedazo-Mînguez A., Huettinger M., Cowburn R.F., Beta-VLDL protects against Aβ(l-42) and apoE toxicity in human SH-SY5Y neuroblastoma cells, NeuroRepon, 12:201-206, 2001
53. Michikawa M., Fan Q.W., Isobe I., Yanagisawa K., Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture, J. Nenrochein., 74:1008-16,2000
54. Wolozin B., Kellman W., Ruosseau P., Celesia GG, Siegel G, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A inhibitors, Arch. Neural., 57:1439-43, 2000
55. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kühl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T., Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta40 in vitro and HI vivo, Proc. Natl. Acad. Sci. USA, 98:5856-61, 2001
56. Poirier J., Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism, Ann. NY Acad. Sci., 924: 81-90, 2000
57. Fan Q.W., Yu W., Senda T., Yanagisawa K., Michikawa M., Cholesterol-dependent modulation of tau phosphorylation in cultured neurons, J. Neurochem., 76:391-400, 2001
58. Arendt T., Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer's disease, Int. J. Dev. NeuroscL, 19:231-45, 2001
59. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E., Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro, Science, 264:850-2, 1994
60. Veinbergs L, Mallory M., Mante M., Rockenstein E., Gilbert J.R., Masliah E., Differential neurotrophic effects of apolipoprotein E in aged transgenic mice, Neurosci. Lett., 265:218-22, 1999
61. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration, J. Neurosci, 19:4867-80, 1999
62. Jope R.S., Song, L., Powers R.E., Cholinergic activation of phosphoinositide signalling is impaired in Alzheimer's disease brain, Nenrobio. Aging, 18:111-120, 1997
63. Ladner C.J., Celesia G.G., Magnuson D.J., Lee J.M., Regional alterations in Ml muscarinic receptor-G protein coupling in Alzheimer's disease, J. Neuropathol. Exp. Neural., 54:783-9, 1995
64. Poirier J., Delisle M-C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P.J. Nalbantoglu B., Gilfix M., Gauthier S., Apolipoprotein E allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease, Proc Natl. Acad. Sci. USA, 92:12260-12264, 1995
65. Soininen H.O., Kosunen S., Helisalmi A., Mannermaa L., Paljarvi S., Talasniemi M., Ryynanen P., Riekkinen S., A severe loss of choline acetyltranferase in the frontal cortex of Alzheimer patients carrying apolipoprotein 4 allele, Neurosci. Lett., 187:79-82, 1995
66. Bronfman F.C, Tesseur L, Hofker M.H., Havekens L.M., Van Leuven R, No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice, Neuroscience, 93:411-8,2000
67. Cedazo-Mînguez A. and Cowburn R.F., Apolipoprotein E isoform-specific disruption of phosphoinositide hydrolysis: protection by estrogen and glutathione, FEES left., In press